Phase 3 Clinical Trials With Primary Completion Dates in January 2018

This is a list of Phase 3 trials with primary completion dates in January 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ANIKAnika Therapeutics Inc.2018-01-01Phase 3NCT02861183Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)
ESPREsperion Therapeutics, Inc.2018-01-01Phase 3NCT03001076Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
RDYDr. Reddy's Laboratories Ltd2018-01-01Phase 3NCT03292640A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
TAROTaro Pharmaceutical Industries Ltd.2018-01-01Phase 3NCT02933866Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
TRPXTherapix Biosciences Ltd.2018-01-01Phase 3NCT03066193Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome